Xenon jumps on pos­i­tive da­ta-to-im­me­di­ate pub­lic of­fer­ing train to bankroll PhI­II epilep­sy study

Af­ter woo­ing in­vestors last Oc­to­ber with a suc­cess­ful Phase IIb, Xenon Phar­ma­ceu­ti­cals is back with more da­ta on an ex­pan­sion study for its dai­ly epilep­sy …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER